Dutch Court Grants Novo Nordisk Preliminary Injunction in Semaglutide Nasal Spray Patent Dispute
Stockholm: Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie from a district court in the Netherlands in a patent infringement case involving a compounded semaglutide nasal spray.
Semaglutide is the active ingredient in Novo Nordisk's weight-loss drug Wegovy.
"The Court found that Ceban infringed Novo Nordisk's supplementary protection certificate (SPC) covering semaglutide," the Danish drugmaker said in a statement.
It said the court ordered Dutch firm Ceban to cease the infringing activities, remove product listings, disclose supply chain information, and reimburse Novo Nordisk's legal costs.
Next Story